12
Participants
Start Date
January 29, 2022
Primary Completion Date
February 16, 2023
Study Completion Date
February 16, 2023
Semaglutide Pill
All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.
Fresh organic vegetables
Prescriptions of organic vegetables
Sansum Diabetes Research Institute, Santa Barbara
Collaborators (1)
Novo Nordisk A/S
INDUSTRY
Sansum Diabetes Research Institute
OTHER